Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Stemline Therapeutics
Deal Size : $570.0 million
Deal Type : Licensing Agreement
Menarini & Insilico Medicine Sign Global License for AI-Discovered Oncology Asset
Details : Under the licensing agreement, Stemline will hold the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $20.0 million
January 10, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Stemline Therapeutics
Deal Size : $570.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Shanghai Pharmaceuticals Holding Co.,Ltd
Deal Size : $608.0 million
Deal Type : Divestment
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
Details : The proceeds will used to develop its pipeline and strategy including its next-generation ADCs for treating patients suffering from cancers.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : $608.0 million
January 01, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Shanghai Pharmaceuticals Holding Co.,Ltd
Deal Size : $608.0 million
Deal Type : Divestment
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical candidate targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable